Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

TIGIT therapy for cancer treatment

Obiettivo

Treating tumors with immune-related therapies is one of the most exciting and promising advancements made in the past decade. Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market. TIGIT is an important checkpoint inhibitory receptor discovered by our group in 2009. It is constitutively expressed by various immune cells and its expression is further increased on tumor infiltrating lymphocytes (TILs). TIGIT recognizes two main ligands, PVR and Nectin2 that are highly expressed on various tumors. Blockage of TIGIT on TILs either alone or in combination with another checkpoint inhibitory receptor, PD-1, leads to increased T and Natural Killer (NK) cell activity in vitro and inhibited tumor growth in vivo. We developed 9 different anti-TIGIT mAbs during my BacNK ERC advanced grant and previously. In the POC grant TIGITtherapy, which already attracted interest from several bio pharma companies, I propose testing which of the 9 anti-TIGIT mAbs and TIGIT-Ig are able to antagonize TIGIT activity.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

ERC-POC - Proof of Concept Grant

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2016-PoC

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

THE HEBREW UNIVERSITY OF JERUSALEM
Contributo netto dell'UE
€ 150 000,00
Indirizzo
EDMOND J SAFRA CAMPUS GIVAT RAM
91904 Jerusalem
Israele
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 150 000,00

Beneficiari (1)